Literature DB >> 18192159

Clinical approaches to minimize rash associated with EGFR inhibitors.

Karen Oishi1.   

Abstract

PURPOSE/
OBJECTIVES: To present a systematic approach for managing the skin rash associated with epidermal growth factor receptor (EGFR)-targeted therapies. DATA SOURCES: Clinical research literature, published abstracts, and clinical experience. The approach presented in this article is based on a combination of clinical experience and consultations with dermatologists, oncologists, and pharmacists familiar with EGFR inhibitor-associated rash. DATA SYNTHESIS: A proactive approach that includes patient education and the use of a grade-based treatment algorithm. The goal of the approach is to minimize the effects of the rash on patients' quality of life and the course of cancer treatment.
CONCLUSIONS: Using the approach described in this article to treat the rash associated with the use of EGFR inhibitors, nurses can lessen patient discomfort and help ensure that patients will continue cancer treatment for as long as necessary. IMPLICATIONS FOR NURSING: The approach described in this article should help nurses to recognize, grade, and treat the skin rash associated with EGFR inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192159     DOI: 10.1188/08.ONF.103-111

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  4 in total

Review 1.  Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.

Authors:  Mario E Lacouture; Kathryn Ciccolini; Richard T Kloos; Mark Agulnik
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

2.  Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.

Authors:  Samuel A Jacobs; James J Lee; Thomas J George; James L Wade; Philip J Stella; Ding Wang; Ashwin R Sama; Fanny Piette; Katherine L Pogue-Geile; Rim S Kim; Patrick G Gavin; Corey Lipchik; Huichen Feng; Ying Wang; Melanie Finnigan; Brian F Kiesel; Jan H Beumer; Norman Wolmark; Peter C Lucas; Carmen J Allegra; Ashok Srinivasan
Journal:  Clin Cancer Res       Date:  2020-11-17       Impact factor: 12.531

3.  Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma.

Authors:  Paulo Ricardo Saquete Martins-Filho; Simone Yuriko Kameo; Ana Carolina Mascarenhas-Oliveira; Nivaldo Farias Vieira; André Luis de Santana Peixoto
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

Review 4.  Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.

Authors:  Beth Eaby-Sandy; Carolyn Grande; Pamela Hallquist Viale
Journal:  J Adv Pract Oncol       Date:  2012-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.